Gilead Sciences Inc

NASDAQ: GILD
$66.16
-$0.77 (-1.2%)
Closing price April 18, 2024
Gilead Sciences Inc is a leading biopharmaceutical company focused on developing and commercializing innovative medicines for life-threatening illnesses worldwide. With a strong emphasis on HIV/AIDS, COVID-19, viral hepatitis, and oncology, Gilead offers a range of treatments that address unmet medical needs. Notable products include Biktarvy, Veklury, and Yescarta. Founded in 1987 and based in Foster City, California, Gilead also engages in significant partnerships to advance its research and development efforts.
Friday's top analyst upgrades and downgrades included CrowdStrike, Exxon Mobil, Ford, Gilead Sciences, Goldman Sachs, Honeywell International, Lowe’s, Lyft, Progressive and Zscaler.
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
Monday afternoon's analyst upgrades and downgrades included American Airlines, Biogen, Citigroup, EA, Gilead, Meta, Micron, Zscaler and more.
24/7 Wall St. screened the Jefferies Franchise Picks, looking for the companies that pay solid dividends and also are strong plays in a very inflationary world. These stocks make good sense for...
Friday's top analyst upgrades and downgrades included Arista Networks, DataDog, FedEx, Fiserv, Gilead Sciences, Global Payments, Nvidia, Oatly, Pfizer, Target, TJX Companies and Victoria’s Secret.
Health care is poised to benefit from a shift toward more defensive sectors. These five stocks have strong balance sheets, attractive dividend yields and improved cost structures. With even moderate...
In this massively overbought market, health care stocks could benefit from a shift toward more defensive sectors. These five offer strong balance sheets, attractive dividend yields and improved cost...
Wednesday's top analyst upgrades and downgrades included Anheuser-Busch, Bank of New York Mellon, Gilead Sciences, Micron Technology, Mosaic, Netflix, Philip Morris International, Synchrony...
While not suited for conservative income investors, these two top biotech stocks could have huge total return potential and offer investors with a touch more risk tolerance some very tempting entry...
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Amazon.com, Edwards Lifesciences, Gilead Sciences, Mastercard and Pinterest.
These four Jefferies stock picks in the health care space offer outstanding upside potential for investors long term and look like very solid ideas for the rest of 2021, especially with an overbought...
24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Amazon, CME, Gilead Sciences and Twitter.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Airbnb, Amazon, Fisker, Peloton, Uber and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Booking, Expedia, FuelCell, Plug Power, Roku and more.
Earnings season is in full swing, and we have put together a preview of some of the world’s largest players in the health care sector reporting this coming week.